Quantcast
Viewing all articles
Browse latest Browse all 9892

Celgene and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-directed Product Candidates

SUMMIT, N.J. & SEATTLE--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that Celgene exercised its option to develop and commercialize the Juno CD19 program outside North America and China. With the exercise of this option, Celgene will pay Juno a fee of $50 million and the companies will now share global development expenses for products in the CD19 program. Celgene has commercial rights outside of North America and China and will

Image may be NSFW.
Clik here to view.
Image may be NSFW.
Clik here to view.

Viewing all articles
Browse latest Browse all 9892

Trending Articles